Title | Clinical Development of PD-1 Blockade in Hematologic Malignancies. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Pianko MJ, Goldberg AD, Lesokhin AM |
Journal | Cancer J |
Volume | 24 |
Issue | 1 |
Pagination | 31-35 |
Date Published | 2018 Jan/Feb |
ISSN | 1540-336X |
Abstract | Clinical development of immune checkpoint inhibitors targeting the PD-1 pathway has led to clinical benefits for patients with multiple solid tumor and hematologic malignancies and has revolutionized modern oncology. High response rates to PD-1 blockade in patients with classical Hodgkin lymphoma and certain subtypes of non-Hodgkin lymphoma highlight an intrinsic biologic sensitivity to this strategy of treatment. Despite early success of checkpoint inhibitor and immunomodulatory drug combinations in phase 2 studies in multiple myeloma, safety concerns in patients treated with the combination of immunomodulatory drugs and checkpoint inhibitors in myeloma have stalled drug development in this space. Novel combination approaches exploring PD-1 inhibitors with epigenetic modifiers in leukemia are underway. |
DOI | 10.1097/PPO.0000000000000297 |
Alternate Journal | Cancer J |
PubMed ID | 29360725 |
PubMed Central ID | PMC5785103 |
Grant List | P30 CA008748 / CA / NCI NIH HHS / United States UL1 TR000457 / TR / NCATS NIH HHS / United States UL1 TR002384 / TR / NCATS NIH HHS / United States |
Submitted by kej2006 on June 6, 2018 - 4:13pm